Fluorogenic Peptide for Active Proteasome Detection in Bladder Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting proteasome activity, particularly in the context of bladder cancer, are time-consuming, non-specific, and require large amounts of biological material, often detecting the entire proteasome population rather than the actively enzymatic fraction.
Innovation Solution
A new peptide compound, ABZ-Dap(O2(Cbz))-Dap(O1)-Dap(O2)-Arg-ANB-NH2, is synthesized using modified diamino acid derivatives with PEG residues, which undergoes selective hydrolysis by proteasome 20S, allowing for sensitive detection of bladder cancer using a simple and rapid fluorescence-based assay in human urine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunochemical techniques (ELISA tests) are used to measure proteasome concentration, then the entire proteasome population can be detected, but the procedure is time-consuming and detects the whole proteasome population rather than the actively enzymatic fraction
Solution Approach 1:
The patent extracts and measures only the actively enzymatic fraction of proteasome by using a fluorogenic substrate that specifically reacts with active proteasome molecules. This approach isolates the functional subset from the total proteasome population, enabling selective detection of the active fraction without measuring inactive forms.
Solution Approach 2:
The patent replaces complex immunochemical techniques with a simpler fluorogenic substrate-based assay. The fluorescent substrate undergoes hydrolysis by active proteasome, producing a measurable fluorescent signal that directly indicates active enzyme presence, eliminating the need for time-consuming antibody-based procedures.
2Measurement precision
If conventional peptide substrates with 4-5 amino acid residues are used, then proteasome activity can be determined, but the sensitivity and specificity for cancer detection are limited
Solution Approach 1:
The patent introduces PEG residues at specific positions within the peptide sequence (positions 2 and/or 3), creating localized modifications that enhance the compound's interaction with proteasome. This local structural enhancement improves sensitivity and specificity for cancer detection without requiring complete redesign of the entire peptide structure.
Solution Approach 2:
The patent creates a composite peptide structure combining traditional amino acid residues with PEG (polyethylene glycol) chains. This composite structure integrates the enzymatic recognition capabilities of the peptide sequence with the enhanced solubility, stability, and binding properties of PEG, resulting in superior detection performance.
3Reliability
If large amounts of biological material are used for detection, then sufficient signal can be obtained, but the requirement for large sample volumes is problematic
Solution Approach 1:
The patent modifies the substrate structure by incorporating PEG residues and optimizing the amino acid sequence to enhance the fluorescent signal generated per unit of proteasome activity. This parameter optimization allows detection with minimal sample volume (50 µl urine) while maintaining strong signal output, eliminating the need for large sample volumes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound achieves a higher sensitivity and specificity for bladder cancer detection, requiring only 50 µl of urine and taking 30 minutes, with a detection limit of 10 pM, effectively identifying active proteasome presence correlated with cancer.
Implementation Method 1
The compound achieves a higher sensitivity and specificity for bladder cancer detection, requiring only 50 µl of urine and taking 30 minutes, with a detection limit of 10 pM, effectively identifying active proteasome presence correlated with cancer
Implementation Method 2
These compounds allow to determine the activity of proteasome, including the presence of proteasome or another proteolytic enzyme. When the C-terminus fluorescent group is released, it tends to be highly fluorescent
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The subject of the invention is a new compound of the following chemical formula: ABZ1 -Dap(02(Cbz))2-Dap(01 )3-Dap(02)4-Arg5-ANB6-NH2 where: ABZ stands for 2-aminobenzoic acid; DAP stands for diaminopropanoic acid (Dap) derivatives, modified by the functionalised residues of mono- ethyl ene or diethyl ene glycol (PEG); ANB stands for 5-amino-2-nitrobenzoic acid The subject of the invention is a method for producing the new compound and a phamiaceutical solution for cancer detection, which contains the above-mentioned compound. The subject of the invention is a method for cancer detection through the in vitro analysis of a human urine sample to which a new compound is added and blended with a buffer of pH 7-9. The subject of the invention is also a kit for detecting cancer, in particular bladder cancer, and the use of hydrolysis of the new compound in the position no. 5 by proteasome 20s for cancer detection, in particular bladder cancer.